Details of Disease

General Information of Disease (ID: DISFZN9R)

• Disease Name: Familial chylomicronemia syndrome
• Disease Class: 5C80: Hyper-lipoproteinaemia
• Disease Hierarchy:
  DIS6SVEE: Syndromic disease
  DISFZN9R: Familial chylomicronemia syndrome
• ICD Code:
  ICD-11: ICD-11: 5C80
  ICD-10: ICD-10: J10, J11
• Disease Identifiers:
  MONDO ID: MONDO_0018637
  UMLS CUI: C5442313
  MedGen ID: 1778100
  Orphanet ID: 444490
  SNOMED CT ID: 1197489003

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Volanesorsen	DM1YEPS	Approved	Antisense oligonucleotide	[1]

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ARO-APOC3	DMABKHH	Phase 3	RNA interference	[2]
Influenza A virus H1N1 vaccine	DMXWNWL	Phase 3	NA	[3]
LCQ908	DMFLJHQ	Phase 3	Small molecular drug	[4]
Olezarsen	DMNLSFN	Phase 3	Antisense oligonucleotide	[5]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT05089084) A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome. U.S.National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of CEL-SCI.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7830).
• [5] ClinicalTrials.gov (NCT05130450) An Open-Label Extension Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS). U.S.National Institutes of Health.